Navigation Links
ViroPharma Announces Securities Repurchase Program
Date:3/9/2011

EXTON, Pa., March 9, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company's Board of Directors has authorized the use of up to $150 million to repurchase shares of its common stock and/or its 2% Senior Convertible Notes due 2017.

Purchases may be made by means of open market transactions, block transactions, privately negotiated purchase transactions or other techniques from time to time, as determined by ViroPharma's management, and in accordance with the requirements of the Securities and Exchange Commission. As of December 31, 2010, ViroPharma had 78,141,491 shares of common stock issued and outstanding.

The sources of cash for this repurchase program are a combination of our cash, cash equivalents and short term investments on our balance sheet and our anticipated cash flows from operations.  ViroPharma produced cash flows of $194 million for the year 2010.

"We are committed to enhancing shareholder value through a variety of efforts," said Charles Rowland, ViroPharma's chief financial officer.  "To that end, today's announcement demonstrates our confidence in the future prospects of our existing business and our ongoing financial strength, which will continue to provide us the ability to pursue additional business development opportunities."

About ViroPharma IncorporatedViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vanc
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ViroPharma to Participate in Two March Healthcare Conferences
2. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
3. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
4. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
5. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
6. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
7. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
8. ViroPharma To Participate in Two September Healthcare Investor Conferences
9. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
10. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
11. ViroPharma to Participate in Two June Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Restore Health, a leading ... pharmaceuticals, announced that it is now offering pharmacogenetics ... each individual based upon their particular genetic makeup. ... the interaction between a patient,s genetics and their ... excited to provide this new service to healthcare ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 ... ), a leading provider of medication and supply ... hold a conference call Thursday, July 31, to ... What:  , Omnicell Second Quarter 2014 earnings ... 2014, 1:30 p.m. PTWho:  , Randall Lipps, chairman, ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... HILL, N.C., June 13, 2011 An organization,s ... stakeholders informed about a company,s vision, commitment, progress ... approach to integrate wide range of scattered activities ... in a continuously changing business environment. ...
... Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel ... Harry S. Palmin, President and CEO of Novelos, will present ... Conference on Thursday, June 16, 2011, at 11:30 a.m. Eastern ... be accessed at www.novelos.com The webcast ...
Cached Medicine Technology:Effective Communications Programs Build Corporate Reputation and Reduce Risk 2Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16 2Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16 3
(Date:7/24/2014)... IL (PRWEB) July 24, 2014 In a ... infertility expert and founder of Lotus Blossom Consulting LLC ... Rosato entitled Three Ways to Cut the High Cost ... way to minimize costs is to maximize your chance of ... advice on choosing a clinic. , “I am always ...
(Date:7/24/2014)... the risk for head and neck cancer (HNC). Evidence suggests ... the risk of HNC in patients with DM has not ... sixth most common type of cancer. It accounts for about ... new cancer cases and 350,000 cancer deaths worldwide each year. ... to examine the risk of HNC in patients with DM. ...
(Date:7/24/2014)... Kan. (PRWEB) July 24, 2014 ... announces that it has achieved certification for compliance ... tested and verified by the DoD Information Assurance ... Vendor Neutral Archive, identified within the DoD as ... Authority to Operate designation from the U.S. Army ...
(Date:7/24/2014)... Hospital and the University of Tennessee Health Science Center ... drug shown to safely reduce the viral load and ... respiratory syncytial virus (RSV). RSV is the most common ... in the United States and worldwide. , The ... John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab has been ...
(Date:7/24/2014)... Moines, IA (PRWEB) July 24, 2014 Members ... keep Michael Wolnerman, RPh, CCIM, Senior Associate of Sales at ... the Governor appointed him to the Board and that his ... , “I want to provide the best I can for ... believe I am uniquely positioned to provide a special insight ...
Breaking Medicine News(10 mins):Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:RSV research breakthrough to help infected children 2Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... Hip resurfacing offers new hope to young osteoarthritic patients. Increasingly ... alternative to hip replacement,// though many sound a note of ... they say. ,At the moment though, whoever ... hip resurfacing surgeons. ,Osteoarthritis is a type ...
... has done herself and her new born proud. The mama is ... baby that was conceived with a frozen egg and sperm.// ... picture about her chances of having a baby with the conventional ... lost all hopes of having a baby, something she wanted more ...
... stranger than fiction. In a first-ever, scientists have ... a source far removed from its origins. Stem ... the new ‘fathers’ of immature sperms, which the scientists hope ... ,The pioneering scientists from the Universities of G?ttingen and Münster ...
... Laval’s Faculty of Medicine have discovered that a compound ... reaction in skin// cells. ,DMAE (2-dimethyl ... anti-aging face-lifts." This compound, as well as other chemically ... shampoos, soaps, and baby lotions, although the way they ...
... what is described as the biggest DNA analysis of whole ... single leap in the understanding of how genes dictate our ... wave of tailored therapies and tests to predict the likelihood ... coalition of 50 groups, including 24 leading human geneticists, has ...
... esophageal reflux testing appear in The American Journal ... College of// Gastroenterology, these guidelines summarize advances in ... they have modified the clinical management of esophageal ... increasing number of patients presenting symptoms of GERD ...
Cached Medicine News:Health News:Hip Resurfacing Fever Catches on in US 2Health News:Hip Resurfacing Fever Catches on in US 3Health News:Breakthrough Discovery- Human Sperms From Bone Marrow 2Health News:Anti-wrinkle Compound Causes Pathological Reaction in Skin Cells 2Health News:UK Scientists to Reveal Genetic Secrets Behind Serious Illnesses 2
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
... is an Auto Refractor/Keratometer with ... refinement. Electronic elevation, automatic alignment, ... accuracy and all the other ... Marco Automatic Refractors/Keratometer famous, make ...
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Medicine Products: